News & Insights
Stay up to date on PsychoGenics’ latest research, press releases, and industry developments in preclinical drug discovery. Combine our expertise with yours to spark the translational power of your next CNS breakthrough.
RESEARCH UPDATES
Characterization of a Mouse and Rat Model of CMT1A
PRESS RELEASES
Unlock New Possibilities with PsychoGenics’ Special Offer!
PRESS RELEASES
PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023
PRESS RELEASES
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PRESS RELEASES
PsychoGenics Launches Updated Corporate Identity and Brand
4 next-gen CNS drug development trends
PODCAST
Changing Drug Discovery for Neuropsychiatric Disorders with Phenotypic Screens
PODCAST
